Activation of the complement system through the alternative pathway is necessary for the development of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in animal models C5a has ...

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...

Researchers had thought complement could be used to fight cancers as part of an antibody-based vaccine, as antibody binding is one of the factors that can set off a complement cascade. However, some ...

InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody Jena, Germany, January 28th 2016 - InflaRx, a ...

This is a preview. Log in through your library . Abstract The polymorphonuclear leukocyte (PMNL) depends on glucose as a source of energy for motility, chemotaxis, phagocytosis, and bactericidal ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...

The FDA’s Arthritis Advisory Committee panelists groped through cloudy data while complaining about the design of the phase III trial for Chemocentryx Inc.’s avacopan, and after going overtime ended ...

The complement system is a central component of innate immunity, consisting of a large family of plasma and membrane bound proteins that are critical for protection against bacterial infection and ...

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...